Eye scan study for ublituximab in multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have relapsing-remitting MS or active secondary progressive MS (a type of MS that comes and goes).
- You are either starting ublituximab (a new MS medication) or are already on a stable MS treatment for at least a year.
- You do not have significant eye disease that could affect the eye scans (like diabetic retinopathy, macular degeneration, or glaucoma).
- You have not received any B-cell depleting MS drugs (like rituximab, ocrelizumab, ofatumumab, or ublituximab) in the last 12 months.
- You do not have a serious active infection (like hepatitis B, tuberculosis, or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.